Literature DB >> 26623248

Cancer Chemoprevention with Korean Angelica: Active Compounds, Pharmacokinetics, and Human Translational Considerations.

Junxuan Lü1, Jinhui Zhang1, Li Li1, Cheng Jiang1, Chengguo Xing2.   

Abstract

Angelica gigas Nakai (AGN) is a major medicinal herb used in Korea and several other Asian countries. Traditionally, its dried root has been used to treat anemia, pain, infection and articular rheumatism, most often through boiling in water to prepare the dosage forms. AGN extract or AGN-containing herbal mixtures are sold in the US and globally as dietary supplements for pain killing, memory enhancement and post-menopausal symptom relief. Decursin (D) and its isomer decursinol angelate (DA) are the major chemicals in the alcoholic extracts of the root of AGN. The anti-cancer activity of AGN alcoholic extract has been established in a number of animal cancer models, including a transgenic model of prostate carcinogenesis. Cell culture structure-activity studies have uncovered distinct cellular and molecular effects of D and DA vs. their pyranocoumarin core decursinol (DOH) with respect to cancer cells and those associated with their microenvironment. Pharmacokinetic (PK) study by us and others in rodent models indicated that DOH is the major and rapid in vivo first-pass liver metabolite of D and DA. Cognizant of metabolic differences among rodents and humans, we carried out a first-in-human PK study of D/DA to inform the translational relevance of efficacy and mechanism studies with rodent models. The combined use of vigorous animal tests and human PK studies can provide stronger scientific rationale to inform design and execution of translational studies to move AGN toward evidence-based herbal medicine.

Entities:  

Keywords:  Angelica gigas Nakai; decursin; decursinol; decursinol angelate; pharmacokinetics; translational cancer research

Year:  2015        PMID: 26623248      PMCID: PMC4662572          DOI: 10.1007/s40495-015-0033-y

Source DB:  PubMed          Journal:  Curr Pharmacol Rep        ISSN: 2198-641X


  46 in total

1.  Differential activation of murine macrophages by angelan and LPS.

Authors:  Y J Jeon; S B Han; K S Ahn; H M Kim
Journal:  Immunopharmacology       Date:  2000-09

2.  Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.

Authors:  Sharon D Morgenbesser; Rajashree P McLaren; Brenda Richards; Mindy Zhang; Viatcheslav R Akmaev; Scott F Winter; Nora D Mineva; Paula J Kaplan-Lefko; Barbara A Foster; Brian P Cook; Michael R Dufault; Xiahong Cao; Clarence J Wang; Beverly A Teicher; Katherine W Klinger; Norman M Greenberg; Stephen L Madden
Journal:  Prostate       Date:  2007-01-01       Impact factor: 4.104

3.  Experimental evidences and signal transduction pathways involved in the activation of NF-kappa B/Rel by angelan in murine macrophages.

Authors:  Y J Jeon; H M Kim
Journal:  Int Immunopharmacol       Date:  2001-07       Impact factor: 4.932

4.  Decursin from Angelicagigas Nakai induces apoptosis in RC-58T/h/SA#4 primary human prostate cancer cells via a mitochondria-related caspase pathway.

Authors:  Sa-Ra Choi; Ju-Hye Lee; Jae-Yong Kim; Kyoung-Wuk Park; Il-Yun Jeong; Ki-Hwan Shim; Mi-Kyung Lee; Kwon-Il Seo
Journal:  Food Chem Toxicol       Date:  2011-06-13       Impact factor: 6.023

5.  Lobe-specific proteome changes in the dorsal-lateral and ventral prostate of TRAMP mice versus wild-type mice.

Authors:  Jinhui Zhang; Lei Wang; Yong Zhang; Li Li; Leeann Higgins; Junxuan Lü
Journal:  Proteomics       Date:  2011-05-20       Impact factor: 3.984

6.  Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.

Authors:  Myung Hwan Jung; Sun Hee Lee; Eun-Mi Ahn; You Mie Lee
Journal:  Carcinogenesis       Date:  2009-02-18       Impact factor: 4.944

7.  Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.

Authors:  Itai Kela; Alon Harmelin; Tova Waks; Avi Orr-Urtreger; Eytan Domany; Zelig Eshhar
Journal:  Prostate       Date:  2009-07-01       Impact factor: 4.104

8.  Characteristic immunostimulation by angelan isolated from Angelica gigas Nakai.

Authors:  S B Han; Y H Kim; C W Lee; S M Park; H Y Lee; K S Ahn; I H Kim; H M Kim
Journal:  Immunopharmacology       Date:  1998-07

9.  Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica Gigas.

Authors:  Hye Hyun Yoo; Min Woo Lee; Young Choong Kim; Chul-Ho Yun; Dong-Hyun Kim
Journal:  Drug Metab Dispos       Date:  2007-07-09       Impact factor: 3.922

10.  Identification of proteins binding to decursinol by chemical proteomics.

Authors:  Hyo Jin Kang; Tae-Sung Yoon; Dae Gwin Jeong; Yongmo Kim; Jin Woong Chung; Jong Seong Ha; Sung Sup Park; Seong Eon Ryu; Sanghee Kim; Kwang-Hee Bae; Sang J Chung
Journal:  J Microbiol Biotechnol       Date:  2008-08       Impact factor: 2.351

View more
  4 in total

1.  Pyranocoumarin Tissue Distribution, Plasma Metabolome and Prostate Transcriptome Impacts of Sub-Chronic Exposure to Korean Angelica Supplement in Mice.

Authors:  Jinhui Zhang; Li Li; Suni Tang; Yong Zhang; Maciej Markiewski; Chengguo Xing; Cheng Jiang; Junxuan Lü
Journal:  Am J Chin Med       Date:  2016       Impact factor: 4.667

2.  Prostate Cancer Xenograft Inhibitory Activity and Pharmacokinetics of Decursinol, a Metabolite of Angelica gigas Pyranocoumarins, in Mouse Models.

Authors:  Wei Wu; Su-Ni Tang; Yong Zhang; Manohar Puppala; Timothy K Cooper; Chengguo Xing; Cheng Jiang; Junxuan Lü
Journal:  Am J Chin Med       Date:  2017-11-09       Impact factor: 4.667

3.  Decursinol-mediated antinociception and anti-allodynia in acute and neuropathic pain models in male mice: Tolerance and receptor profiling.

Authors:  LaTaijah C Crawford; Sangyub Kim; Deepkamal Karelia; Diana E Sepulveda; Daniel J Morgan; Junxuan Lü; Angela N Henderson-Redmond
Journal:  Front Pharmacol       Date:  2022-09-29       Impact factor: 5.988

4.  Effects of Angelica gigas Nakai as an Anti-Inflammatory Agent in In Vitro and In Vivo Atopic Dermatitis Models.

Authors:  Seon Ok; Sa-Rang Oh; Tae-Sung Jung; Sang-Ok Jeon; Ji-Wook Jung; Deok-Seon Ryu
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-11       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.